BC Innovations | Nov 9, 2016
Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting HDLBP could help treat atherosclerosis in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). In 10 NAFLD patients, 10 NASH patients and 5...
Items per page:
1 - 1 of 1